| A personalized CYP2C19 phenotype-guided dosing regimen of voriconazole using a population pharmacokinetic analysis Y Kim, S Rhee, WB Park, KS Yu, IJ Jang, SH Lee Journal of Clinical Medicine 8 (2), 227, 2019 | 17 | 2019 |
| Development of a Korean‐specific virtual population for physiologically based pharmacokinetic modelling and simulation Y Kim, O Hatley, S Rhee, S Yi, HA Lee, S Yoon, JY Chung, KS Yu, H Lee Biopharmaceutics & Drug Disposition 40 (3-4), 135-150, 2019 | 16 | 2019 |
| A pharmacokinetic drug-drug interaction study between pregabalin and tramadol in healthy volunteers S Lee, Y Kim, JJS Lee, G Im, JY Cho, JY Chung, S Yoon European Journal of Clinical Pharmacology 74, 1605-1613, 2018 | 14 | 2018 |
| Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects Y Kim, S Yoon, Y Choi, SH Yoon, JY Cho, IJ Jang, KS Yu, JY Chung Scientific Reports 9 (1), 1-10, 2019 | 13 | 2019 |
| Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment S Yoon, S Yi, S Rhee, HA Lee, Y Kim, KS Yu, JY Chung Translational and Clinical Pharmacology 27 (3), 107-114, 2019 | 11 | 2019 |
| Pharmacokinetics, safety, and tolerability of tedizolid phosphate after single-dose administration in healthy Korean male subjects Y Kim, A Kim, SH Lee, SH Choi, DY Lee, JS Song, H Lee, IJ Jang, KS Yu Clinical Therapeutics 39 (9), 1849-1857, 2017 | 10 | 2017 |
| Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects Y Kim, S Lee, Y Kim, IJ Jang, SH Lee Clinical and Translational Science 15 (2), 422-432, 2022 | 7 | 2022 |
| Pharmacokinetics of Ginsenoside Compound K From a Compound K Fermentation Product, CK‐30, and From Red Ginseng Extract in Healthy Korean Subjects MS Ban, Y Kim, S Lee, BY Han, KS Yu, IJ Jang, HK Chung, SH Lee Clinical Pharmacology in Drug Development 10 (11), 1358-1364, 2021 | 7 | 2021 |
| Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation Y Kim, A Kim, JY Chung Journal of Affective Disorders 285, 120-126, 2021 | 7 | 2021 |
| Clinical response and hospital costs of therapeutic drug monitoring for vancomycin in elderly patients Y Kim, S Kim, J Park, H Lee Journal of Personalized Medicine 12 (2), 163, 2022 | 6 | 2022 |
| Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors HK Kim, JW Kang, YW Park, JY Kim, M Kim, SJ Kim, S Kim, K Ho Ryu, ... Pharmacology research & perspectives 8 (2), e00568, 2020 | 5 | 2020 |
| Mass Cytometry Study on Hepatic Fibrosis and Its Drug-Induced Recovery Using Mouse Peripheral Blood Mononuclear Cells J Bae, JE Kim, H Perumalsamy, S Park, Y Kim, DW Jun, TH Yoon Frontiers in Immunology 13, 13, 2022 | 4 | 2022 |
| Pharmacokinetic/pharmacodynamic interaction between evogliptin and pioglitazone in healthy male subjects I Hwang, Y Kim, H Yoo, IJ Jang, KS Yu, SH Lee Drug Design, Development and Therapy, 4493-4502, 2020 | 4 | 2020 |
| ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model EJ Lee, Y Kim, JE Kim, EL Yoon, SR Lee, DW Jun Life 13 (1), 100, 2022 | 3 | 2022 |
| Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects H Yoo, Y Kim, IJ Jang, KS Yu, SH Lee Drug Design, Development and Therapy, 5179-5187, 2020 | 2 | 2020 |
| Regulation of Hepatocyte Nuclear Factor 4α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease YJ Roh, Y Kim, JS Lee, JH Oh, SM Lee, EL Yoon, SR Lee, DW Jun Life 12 (11), 1682, 2022 | 1 | 2022 |
| Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults S Im Jeong, Y Kim, JJ Nah, W Huh, IJ Jang, JG Hwang, SH Lee British Journal of Clinical Pharmacology, 2022 | 1 | 2022 |
| Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults SI Jeong, Y Kim, JJ Nah, W Huh, IJ Jang, JG Hwang, SH Lee British Journal of Clinical Pharmacology, 2022 | | 2022 |
| Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects B Kim, KY Huh, JG Hwang, JJ Nah, W Huh, JM Cho, IJ Jang, KS Yu, ... British Journal of Clinical Pharmacology, 2022 | | 2022 |
| Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers Y Kim, K Bo-Hyung, SH Lee International Journal of Clinical Pharmacology and Therapeutics 55 (1), 102, 2017 | | 2017 |
